Agile Therapeutics (AGRX)
(Delayed Data from OTC)
$0.40 USD
+0.03 (8.19%)
Updated Apr 24, 2024 03:03 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Agile Therapeutics, Inc. [AGRX]
Reports for Purchase
Showing records 1 - 20 ( 51 total )
Company: Agile Therapeutics, Inc.
Industry: Medical - Generic Drugs
New Tailwinds Support Twirla Prospects; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Agile Therapeutics, Inc.
Industry: Medical - Generic Drugs
Twirla Volume Ramp Lends Credibility to Breakeven Prospects and/or Takeout Upside; Target to $12; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Agile Therapeutics, Inc.
Industry: Medical - Generic Drugs
Company: Agile Therapeutics, Inc.
Industry: Medical - Generic Drugs
Strong Twirla Non-Retail Follow-Through Bodes Well for 4Q and Beyond; Price Target Down to $3 but Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Agile Therapeutics, Inc.
Industry: Medical - Generic Drugs
2Q22: Impressive OPEX Streamlining With Sustained Twirla Growth; Twirla Tailwinds Increasing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Agile Therapeutics, Inc.
Industry: Medical - Generic Drugs
Twirla Tailwinds as ACA-Mandated Contraceptive Access Is Key Post Roe; Reiterate Buy; Price Target Up To $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Agile Therapeutics, Inc.
Industry: Medical - Generic Drugs
Washington Turning the ACA Screws on Payers to Fully Cover Twirla; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Agile Therapeutics, Inc.
Industry: Medical - Generic Drugs
Twirla Ramping, But Slowly; Will Washington Enforce ACA Contraceptive Mandate? Lower PT to $2.50, Maintain Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Agile Therapeutics, Inc.
Industry: Medical - Generic Drugs
Company: Agile Therapeutics, Inc.
Industry: Medical - Generic Drugs
Twirla Still Getting Its Footing; Lowering Sales and Target to $3.50, But Maintain Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Agile Therapeutics, Inc.
Industry: Medical - Generic Drugs
1Q21: Groundwork Laid, Now Twirla Is Accelerating; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Agile Therapeutics, Inc.
Industry: Medical - Generic Drugs
4Q20: Very Early Twirla Days, But Prescription Showing Up Despite Sample Saturation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Agile Therapeutics, Inc.
Industry: Medical - Generic Drugs
Twirla Launches After Clearing Last Hurdles; Expect Trends Post-COVID Surge to Impress; Raise to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Agile Therapeutics, Inc.
Industry: Medical - Generic Drugs
3Q20: Twirla Sales Force Priming the Pump Ahead of December Launch Stocking; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Agile Therapeutics, Inc.
Industry: Medical - Generic Drugs
Twirla Prepped for 4Q Launch; Likely Coverage and Patient Access at Launch Underappreciated by Street; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Agile Therapeutics, Inc.
Industry: Medical - Generic Drugs
2Q20: Pedal to the Metal for 4Q Twirla Launch; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Agile Therapeutics, Inc.
Industry: Medical - Generic Drugs
With Approval and Cash in Hand, Pushing Toward a 4Q Twirla Launch; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Agile Therapeutics, Inc.
Industry: Medical - Generic Drugs
Well Capitalized and Underappreciated; Pandemic Wont Preempt Launch Prep; Tweak Down Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Agile Therapeutics, Inc.
Industry: Medical - Generic Drugs
Twirla Finally Approved; BMI Limitation Doesnt Faze Us; Expect 4Q Launch; Raise to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Agile Therapeutics, Inc.
Industry: Medical - Generic Drugs
Twirla Rollercoaster Back on the Rise; AdCom Yields Near Unanimous Positive Vote Despite FDA Resistance
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O